Forbion leads €17m series-C for Omeicos

Forbion drew capital from its latest fund, Forbion Capital Fund IV, which held a final close on €360m in September.

The VC firm was joined by existing investors Vesalius Biocapital, Remiges BioPharma Fund, SMS Group, KfW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds (HTGF) and The Falck Revocable Trust.

The proceeds from this round will finance Promise-AF, a placebo-controlled, double-blinded and randomised dose-finding phase-II study on the candidate drug OMT-28 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation.

It will also be used to continue the development of the company's ophthalmology operations, which are mostly conducted in Boston.

Previous funding
Vesalius, HTGF, IBB Beteiligungsgesellschaft and KfW led a €6.2m series-A for Omeicos in 2015, and the same syndicate injected an additional €8.3m into the company's series-B in March 2017.

The series-B was extended in October 2017, led by US-based Remiges Ventures with support from all existing investors. The volume of the extension was not disclosed.

Company
Omeicos was founded in 2013 as a spin-out from the Max Delbrück Center in Berlin. Its technology is based on research conducted by the company's founders, Wolf-Hagen Schunck, John Falck, Dominik Müller and Robert Fischer. It develops drugs to treat inflammatory, cardiovascular and opthalmology diseases, among others. The company is headquartered in Berlin with additional operations in Boston.

People
Forbion Capital Partners – Holger Reithinger (partner).
Vesalius Biocapital – Christian Schneider (managing partner).
Omeicos Therapeutics – Robert Fischer (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• High-Tech Gründerfonds
• Venture